Why defect size is the deciding factor

When a consultant raises both OATS and osteochondral allograft (OCA) as options, the question patients most often ask is: what makes one the right choice over the other? In most cases, the answer comes down to a single variable — the size of the defect.

Both procedures share the same biological aim: replacing damaged cartilage with genuine hyaline cartilage, which is mechanically stronger and more durable than the fibrocartilage that forms after simpler techniques such as microfracture. What differs is where the replacement tissue comes from. OATS harvests plugs from the patient's own knee; OCA uses a precisely matched fresh donor graft. That distinction directly determines their respective limits.

OATS is suited to smaller focal defects — typically 1–2 cm², or up to around 4 cm² when multiple plugs are used in a mosaic pattern. Once a defect grows beyond what the patient's own knee can safely donate without significant morbidity, OCA becomes the established route, with no equivalent ceiling on coverage.

Both techniques are primarily offered to younger, active patients with symptomatic focal cartilage loss who are not yet appropriate candidates for joint replacement. The choice between them is not a question of superiority — it is a question of scale.

What OATS involves and when it fits

The procedure begins at a low-load region of the patient's own knee — typically the periphery of the femoral condyle, where cartilage is present but rarely under full weight-bearing stress. The surgeon cores out one or more cylindrical plugs of bone and cartilage, then press-fits them into the prepared defect site, much like filling a pothole with a matching core of road material taken from a quieter stretch of the same road. Size and depth are matched as precisely as the anatomy allows, and the plug locks in place by compression rather than supplemental fixation.

Because every component of the graft comes from the patient, there is no immunological barrier to navigate: no donor matching, no tissue bank to wait for, no laboratory culture step. Harvest and implantation happen in a single operation, typically lasting around 90 minutes to two hours, which keeps both surgical complexity and cost relatively contained — UK private pricing runs to approximately £14,000 all-inclusive, compared with roughly double that for a fresh allograft procedure.

The one practical ceiling on OATS is the donor site itself. Harvesting more plugs than the low-load zone can safely provide risks creating a symptomatic defect where none existed before, so the technique is reserved for smaller focal lesions where the available harvest volume is sufficient. Published long-term data comparing autograft against microfracture support its durability in appropriately selected patients, and that evidence is examined in detail later in this article.

When osteochondral allograft becomes the better option

Once a defect exceeds what the patient's own knee can safely donate, the replacement tissue must come from elsewhere. OCA addresses this by sourcing a size-matched plug — or, for geometrically complex cases, a contoured shell — of cartilage and underlying bone from a regulated human tissue bank, implanting it directly into the prepared defect in a single operation.

For contained condylar lesions between 15 and 35 mm in diameter, the standard approach is a cylindrical press-fit plug. Round condylar geometry suits a cored donor graft well: once seated, the plug achieves stability through compression alone, without screws or supplemental fixation. Posterior femoral condyle and tibial plateau lesions are less amenable to this technique — access angles and surface contour make a circular coring system impractical. For these sites, or where the defect is elongated or irregular in outline, a shell allograft — a section of donor tissue shaped to match the lesion — is the preferred variant.

Fresh grafts are used in preference to frozen ones for a straightforward biological reason: chondrocytes survive better at low temperatures than under cryogenic storage conditions, so a fresh graft arrives with a substantially higher proportion of viable living cells. Fresh tissue also allows thorough donor screening before clinical release.

The cost — approximately £28,000 in UK private practice — reflects the accredited tissue bank supply chain, the human tissue regulatory framework, and the logistics of matching and transporting a viable graft within a narrow window of viability. It is this infrastructure that makes OCA the practical solution for large defects that autograft volume simply cannot fill.

What the outcome evidence shows

The outcome numbers for OCA come from reasonably well-followed cohorts. In a series of 149 knees tracked to a mean of six years, roughly three in four patients (75.2%) returned to sport or recreational activity, seven in ten achieved very good or excellent knee function, and 79% were participating in high-level activity on the IKDC subjective evaluation — figures drawn from patients with symptomatic large cartilage lesions, the population for whom the procedure is indicated.

Patellofemoral OCA series extend the horizon further: graft survival reached 87.9% at five years and 77.2% at ten years, with aggregate IKDC scores improving from 41.8 before surgery to 68.1 afterwards (P < 0.001). That ten-year mark is clinically significant for a population that is typically too young for joint replacement. Beyond it, Raz et al. reported distal femoral fresh OCA outcomes at a mean follow-up of 22 years, and Gross et al. (2008) documented long-term results in posttraumatic knee defects — collectively suggesting that well-integrated grafts can remain functional across decades. When primary grafts do eventually fail, revision OCA has been shown to be a viable option (Horton et al., AJSM 2013), so a first allograft does not foreclose further joint-preserving surgery.

For OATS, the ten-year data from Gudas et al. (2012) are most relevant in a specific context: patients with smaller focal defects — typically in the 1–2 cm² range — where available harvest volume was adequate. In that carefully selected population, autograft consistently outperformed marrow-stimulation over the same period. The caveat is that the study does not address what happens when the defect edges into the intermediate range or harvest volume becomes marginal.

That gap matters. No published randomised trial has directly compared OATS against OCA for intermediate-sized defects — roughly 1 to 4 cm² — where both techniques are plausible candidates. Decisions in that range rest on individual anatomy, surgeon experience, and patient priorities rather than head-to-head trial data. This is not a reason to distrust either procedure; it is simply why a specialist assessment is where the choice gets meaningfully resolved.

Other factors that shape the choice: location, recovery, and setting

Defect location adds a layer of complexity that size alone does not capture. Where plug OCA and OATS share broadly similar technical demands on the central femoral condyle, lesions at anatomically awkward sites — those involving difficult access angles or irregular surface contour — tend to require a shell allograft approach, as discussed in the context of surgical technique above. Imaging to map both the position and the boundaries of the defect is therefore part of any pre-operative assessment.

Recovery length is the variable most patients ask about after cost. OCA typically requires touch-down weight bearing for four to six weeks, with return to low-impact activity from around four to six months and high-impact sport from nine to twelve months. OATS, as a smaller procedure in a correctly selected patient, generally allows an earlier functional return. The longer OCA timeline is not an argument against it in the appropriate case — undertreating a large defect with an autograft that cannot adequately fill it carries a greater risk of failure than accepting the extended recovery.

OCA also depends on tissue bank availability: the graft must be matched in size, sourced from an accredited bank, and used within a narrow viability window. OATS carries no equivalent logistical constraint — donor tissue is harvested and implanted in the same operation, with no scheduling dependence on external supply.

Finally, where a varus or valgus alignment abnormality is placing abnormal load on the damaged compartment, an osteotomy to correct that alignment is addressed as a separate joint-preservation step — staged alongside or in advance of the cartilage procedure, not as part of the graft technique itself.

Finding a knee cartilage specialist in the UK

Choosing between these two techniques is not a decision that can be made from article reading alone — it requires MRI assessment, clinical examination, and a surgeon who operates at volume in osteochondral procedures. Not every orthopaedic surgeon offers both OATS and OCA routinely; the techniques are demanding, and outcomes in published series tend to reflect specialist practice. Patients are therefore well served by identifying a consultant who works regularly in this area before committing to a pathway.

Search MSK lists knee cartilage specialists across the UK — filter by region and specialty to find one near you. The most useful question to bring to that appointment is not which procedure to request, but an honest account of symptoms, activity level, and any previous interventions: the defect characteristics, once properly imaged, will determine which approach — if either — genuinely fits.